Iovance Biotherapeutics Current Cash

Iovance Biotherapeutics (0JDK.L) currently reports a current cash of $110M as of June 2026. That compares with $130M in the prior-year period — down 16.4% year over year. Use the charts on this page to explore Iovance Biotherapeutics's current cash history and peer comparisons.

Iovance Biotherapeutics's current cash decreased from $130M to $110M — a 16.4% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Iovance Biotherapeutics reported $110M in current cash as of June 2026. That compares with $130M in the prior-year period — down 16.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $110M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Iovance Biotherapeutics, and consider following 0JDK.L for alerts when major investors trade the stock.

Iovance Biotherapeutics is classified in the Healthcare sector. On current cash, it currently shows $110M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 0JDK.L with unrelated industries.